LEADER 00832nam0-22002891i-450- 001 990001317910403321 035 $a000131791 035 $aFED01000131791 035 $a(Aleph)000131791FED01 035 $a000131791 100 $a20000920d1971----km-y0itay50------ba 101 0 $aeng 200 1 $aDifferentials of commutative rings$fSatoshi Suzuki 210 $aKingston [Ontario]$cQueen's University$d1971 215 $a162 p., 28 cm 225 1 $aQueen's papers in pure and applied mathematics$v29 610 0 $aAlgebra differenziale 676 $a512.56 700 1$aSuzuki,$bSatoshi$059706 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001317910403321 952 $aC-44-(29$b10161$fMA1 959 $aMA1 996 $aDifferentials of commutative rings$9382468 997 $aUNINA DB $aING01 LEADER 03808nam 22004455 450 001 9910303443003321 005 20251116212906.0 010 $a3-030-02505-5 024 7 $a10.1007/978-3-030-02505-2 035 $a(PPN)232960534 035 $a(CKB)4100000007204825 035 $a(MiAaPQ)EBC5614210 035 $a(DE-He213)978-3-030-02505-2 035 $a(EXLCZ)994100000007204825 100 $a20181211d2018 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aImmunotherapy /$fedited by Aung Naing, Joud Hajjar 205 $a2nd ed. 2018. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018. 215 $a1 online resource (183 pages) 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v995 311 08$a3-030-02504-7 327 $aOverview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies . 330 $aThe second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book?s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science. 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v995 606 $aOncology 606 $aCancer Research$3http://scigraph.springernature.com/things/product-market-codes/B11001 615 0$aOncology. 615 14$aCancer Research. 676 $a616.9046 702 $aNaing$b Aung$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aHajjar$b Joud$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910303443003321 996 $aImmunotherapy$92019290 997 $aUNINA